Injectable Microgel Assemblies for Localized Immune Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Vascularized composite allotransplantation (VCA) faces significant challenges due to allospecific T cell-dependent rejection, necessitating lifelong immunosuppression with associated side effects, and current immunotherapies fail to completely prevent chronic graft loss.

Innovation Solution

The development of microgel assemblies comprising microgels with peptides of either D-amino acids or L-amino acids, combined with immune modifying agents, which are applied to the site of tissue engraftment to modulate the immune response and promote tissue integration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If lifelong immunosuppression is administered to prevent VCA rejection, then graft acceptance is improved, but patient health deteriorates due to side effects including hyperglycemia, neuropathy, infections, and cancer

Engineering Contradiction:

Improvegraft acceptanceVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent divides the immunosuppressive effect into localized segments at the graft site rather than systemic administration. Microgels are applied directly to the transplant site, creating localized immunomodulatory zones that affect only the graft area and surrounding tissue, not the entire body. This segmentation allows graft protection without systemic immunosuppression side effects.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention implements local quality by concentrating immunomodulatory agents precisely at the graft site through microgel application. The microgels create a localized therapeutic environment with high concentrations of immune-modulating substances exactly where needed, while maintaining normal immune function in the rest of the body, thereby avoiding systemic side effects.

Inventive Principle:

Principle #3Local quality

2Reliability

If current immunotherapies are used to prevent rejection, then short-term graft acceptance is improved, but long-term graft survival deteriorates due to chronic graft loss

Engineering Contradiction:

Improveshort-term graft acceptanceVSAvoidlong-term graft survival

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by administering immunomodulatory microgels at the time of transplantation and continuing through the critical early rejection period. This preliminary immunomodulation primes the immune system to tolerate the graft before alloreactive T cell responses can establish chronic rejection, thereby improving both short-term acceptance and long-term survival.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention ensures continuity of useful action through sustained-release microgels that continuously deliver immunomodulatory agents over extended periods. The microgels maintain therapeutic concentrations of immune-modulating substances throughout the critical window from immediate post-transplant through long-term graft survival, preventing both acute and chronic rejection.

Inventive Principle:

Principle #20Continuity of useful action

3Reliability

If multi-drug regimens are administered to prevent rejection, then immune protection is improved, but treatment complexity increases with multiple medications including calcineurin inhibitors, antimetabolites, and glucocorticosteroids

Engineering Contradiction:

Improveimmune protectionVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges multiple immunomodulatory functions into a single microgel formulation. The microgels can encapsulate multiple different immunomodulatory agents (such as cytokines, chemokines, or pharmacological agents) in one delivery system, replacing the need for multiple separate medications and simplifying the treatment regimen while maintaining comprehensive immune protection.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention implements universality by designing microgels with multi-functional capabilities. A single microgel formulation can simultaneously provide immunosuppression, anti-inflammatory effects, and tissue protection functions that previously required multiple different medications, thereby reducing treatment complexity while maintaining robust immune protection.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250134957A1Modular biomaterial platform local, injectable delivery of a drug and methods of making and using same

Publication Date: 2025.05.01 DUKE UNIV

AI summary

Microgel assemblies provide an injectable and tunable microporous scaffold for immune cell modulation. Leukocytes from graft recipients can migrate into and integrate within the microgel assembly to induce immunological tolerance for the graft without the need for chronic immunosuppressive therapy. The microgel assembly can be used to treat for tissue graft and to reduce an alloreactive immune response following a tissue graft.